|

PErsonalized TReatment for Endometrial Carcinoma

RECRUITINGN/ASponsored by University of Helsinki
Actively Recruiting
PhaseN/A
SponsorUniversity of Helsinki
Started2022-02-08
Est. completion2028-12-31
Eligibility
Age18 Years – 100 Years
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05655260

Summary

The goal of this clinical trial is to compare the efficacy of adjuvant therapies in women with stage I-II molecular integrated high-intermediate or high-risk endometrial carcinoma. Specifically, the invesigators want to compare: * Chemotherapy vs. chemoradiotherapy in p53 abn subtype and nonendometrioid carcinomas. * Vaginal brachytherapy vs. whole pelvic radiotherapy in the MMR-D molecular subgroup. * Vaginal brachytherapy vs. whole pelvic radiotherapy in the NSMP molecular subgroup.

Eligibility

Age: 18 Years – 100 YearsSex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* Age 18 to 100 years
* WHO performance status 0 to 2
* Stage I-II molecular integrated high-intermediate or high-risk endometrial carcinoma

Exclusion Criteria:

* Age \<18 years or \>100 years
* WHO performance status \>2
* Uterine sarcoma
* A history of malignancy within 5 years
* Previous pelvic radiotherapy
* An interval of \>30 days between surgery and start of chemotherapy or \>8 weeks between surgery and start of radiotherapy (longer intervals may be permitted with investigator´s approval)

Conditions2

CancerEndometrial Adenocarcinoma

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.